Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

Phase 3 trial investigating Rozanolixizumab for adult primary immune thrombocytopenia has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: TERMINATED | Results posted: 2023-08-08